Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method.

Borowitz, Michael J; Wood, Brent L; Keeney, Michael; Hedley, Benjamin D

Borowitz, Michael J; Wood, Brent L; Keeney, Michael; Hedley, Benjamin D.

Afiliación

Borowitz MJ; Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Wood BL; Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Keeney M; Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario.
Hedley BD; Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario.

Curr Protoc ; 2(3): e383, 2022 Mar.

Article en En | MEDLINE | ID: mdl-35263042

Asunto(s)

Leucemia-Linfoma Linfoblástico de Células Precursoras; Enfermedad Aguda; Antígenos CD19; Niño; Citometría de Flujo/métodos; Humanos; Neoplasia Residual/diagnóstico; Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico; Estados Unidos

Palabras clave

B-acute lymphoblastic leukemia; Children's Oncology Group; MRD; acute leukemia; flow cytometry; standardization

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies País/Región como asunto: America do norte Idioma: En Revista: Curr Protoc Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google